For millions of women and elderly individuals worldwide, urinary tract infections (UTIs) represent more than just occasional discomfort; they pose a persistent health challenge with increasingly limited treatment options. While modern diagnostic tools can detect UTIs faster and more accurately than ever, this advancement has not led to better solutions for patients or healthcare providers. Faced with tightening regulations and a shrinking arsenal of effective antibiotics, doctors find themselves prescribing the same diminishing pool of medications, even as bacterial resistance continues to grow. On the other hand, the search for effective prevention has seen multiple approaches come and go. Protein-based vaccines showed early promise but failed to deliver protection in clinical trials. Sugar-based conjugate vaccines, successful against other diseases, have struggled with UTIs. Meanwhile, the supplement aisles overflow with probiotic blends and cranberry extracts claiming to prevent infections, but without rigorous clinical testing or consistent manufacturing standards, their effectiveness remains questionable at best. At Spectre Bio, we are taking a fundamentally different path with our BLiP (Bacterial-Like Particle) technology. Rather than isolating individual bacterial components or relying on untested formulations, we have developed a way to present the immune system with complete bacterial surfaces, minus the genetic material that could cause infection. It is like presenting the immune system with a full "wanted poster" of the pathogen, not just a fingerprint. This genome-free approach combines the best features of different preventive strategies while avoiding their pitfalls. Like whole-cell vaccines, BLiPs display all the important surface markers in their native form to elicit strong immunity. Like the safest subunit vaccines, they contain no live components. And unlike inconsistent supplement products, every batch undergoes strict quality control and will be developed to meet clinically proven standards recognised by major regulatory bodies. This project focuses on engineering BLiPs specifically tailored to target uro-pathogens, particularly uro-pathogenic E. coli, the primary cause of most UTIs. By optimising both the design and manufacturing process, we aim to develop a prevention tool that can: 1\. Reduce antibiotic use by preventing infections before they occur 2\. Provide consistent protection for individuals suffering recurrent UTIs 3\. Establish a new model for combating other antibiotic-resistant infections With UTIs becoming increasingly difficult to treat, prevention is no longer just preferable; it is becoming essential. This project represents a critical step toward making that prevention safe, effective, and accessible to those who need it most.